HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of levosimendan in rat mesenteric ischemia/reperfusion injury.

AbstractBACKGROUND:
Intestinal ischemia reperfusion (IR) is associated with morbidity and mortality. We first examined the role of levosimendan in the protection of intestine after mesenteric IR.
METHODS:
The rats were divided into six groups: (1) Control group; (2) Levosimendan group; (3) Ischemia group (60 min of occlusion); (4) IR group (60 min of occlusion and then 60 min reperfusion); (5) IR + 1 mg/kg levosimendan group: Levosimendan was given intraperitonally 30 min prior to the ischemia; (6) IR + 2 mg/kg levosimendan group.
RESULTS:
The levels of TNF-α, IL-6, and IL-1β were found to have increased in the IR group. The serum levels of TNF-α, IL-6, and IL-1β were found to have decreased as a result of the administration of both doses of levosimendan in the IR. Relative TNF-α and NFκB mRNA levels was decreased by administration of both doses of levosimendan in the IR. SOD activity and GSH levels for IR group were lower than, and 8-ISO levels were higher than, those of the sham-operated rat and ischemia alone group.
CONCLUSIONS:
Both doses of levosimendan had preventive effects on the alterations that occurred in the intestinal tissues after IR. Levosimendan administration attenuated in reperfusion injury of intestine and consequently protects intestinal mucosa and oxidant-antioxidant balance of ileum.
AuthorsBeyzagul Polat, Abdulmecit Albayrak, Zekai Halici, Emre Karakus, Yasin Bayir, Elif Demirci, Elif Cadirci, Ersan Odaci, Muhammed Yayla, Sabri Selcuk Atamanalp
JournalJournal of investigative surgery : the official journal of the Academy of Surgical Research (J Invest Surg) Vol. 26 Issue 6 Pg. 325-33 (Dec 2013) ISSN: 1521-0553 [Electronic] United States
PMID23957729 (Publication Type: Journal Article)
Chemical References
  • Hydrazones
  • Interleukin-1beta
  • Interleukin-6
  • NF-kappa B
  • Pyridazines
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Simendan
Topics
  • Animals
  • Hydrazones (therapeutic use)
  • Interleukin-1beta (blood)
  • Interleukin-6 (blood)
  • Intestines (blood supply, pathology)
  • NF-kappa B (genetics)
  • Pyridazines (therapeutic use)
  • RNA, Messenger (metabolism)
  • Rats
  • Reperfusion Injury (pathology, prevention & control)
  • Simendan
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: